non fda approved glp 1 restricts GLP-1 ingredients in non-approved compounded drugs | FDA posted on the topic The GLP-1 Wars Just Went

[9] Beyond GLP-1s Beyond GLP-1based agents, additional peptide approaches are under exploration

Strengthen the skin barrier and reduce sensitivity and redness

Research demonstrates that ipamorelin administration completely counteracted glucocorticoid-induced decreases in bone formation

Serious Safety Concerns Associated With Saxenda Severe Gastrointestinal Motility Disorders Reported injuries include: gastroparesis (stomach paralysis) ileus (functional bowel shutdown) severe constipation chronic digestive dysfunction Related: Motility Disorders Dehydration & Kidney Injury Ongoing vomiting or reduced intake may lead to: dehydration electrolyte imbalance acute kidney injury (AKI) worsening kidney disease Related: Dehydration and Kidney Damage Gallbladder Disease Weight loss and altered bile flow may increase the risk of: gallstones gallbladder inflammation gallbladder removal surgery Related: Gallbladder Removal Pancreatitis Some patients report: severe abdominal pain elevated pancreatic enzymes hospitalization for pancreatitis Related: Pancreatitis Vision Problems / NAION Serious vision complications, including Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) , have been reported across the GLP-1 drug class

Conclusion L-arginine is a dietary supplement used to enhance health benefits and to treat diseases related to decreased blood flow